  Recently, drug repurposing has emerged as an effective and resource-efficient
paradigm for AD drug discovery. Among various methods for drug repurposing,
network-based methods have shown promising results as they are capable of
leveraging complex networks that integrate multiple interaction types, such as
protein-protein interactions, to more effectively identify candidate drugs.
However, existing approaches typically assume paths of the same length in the
network have equal importance in identifying the therapeutic effect of drugs.
Other domains have found that same length paths do not necessarily have the
same importance. Thus, relying on this assumption may be deleterious to drug
repurposing attempts. In this work, we propose MPI (Modeling Path Importance),
a novel network-based method for AD drug repurposing. MPI is unique in that it
prioritizes important paths via learned node embeddings, which can effectively
capture a network's rich structural information. Thus, leveraging learned
embeddings allows MPI to effectively differentiate the importance among paths.
We evaluate MPI against a commonly used baseline method that identifies anti-AD
drug candidates primarily based on the shortest paths between drugs and AD in
the network. We observe that among the top-50 ranked drugs, MPI prioritizes
20.0% more drugs with anti-AD evidence compared to the baseline. Finally, Cox
proportional-hazard models produced from insurance claims data aid us in
identifying the use of etodolac, nicotine, and BBB-crossing ACE-INHs as having
a reduced risk of AD, suggesting such drugs may be viable candidates for
repurposing and should be explored further in future studies.
